Future Medicine India Magazine - May 2021
Future Medicine India Magazine - May 2021
Go Unlimited with Magzter GOLD
Read Future Medicine India along with 8,000+ other magazines & newspapers with just one subscription View catalog
1 Month $9.99
Subscribe only to Future Medicine India
Subscription plans are currently unavailable for this magazine. If you are a Magzter GOLD user, you can read all the back issues with your subscription. If you are not a Magzter GOLD user, you can purchase the back issues and read them.
In this issue
Even as India is trying out various models to fine- tune and scale up its vaccination strategy, more and more cases are coming up involving re-infections and breakthrough infections — where the infection takes place despite the completion of a full course of vaccination. To make matters worse, many such cases are being reported among the frontline warriors, especially in healthcare settings. This edition makes a deep dive analysis of this challenging issue along with other interesting breakthrough developments in the medical science and clinical arena.
Covid-19: India To Vaccinate All Above 18
The central government has started vaccination for everyone above the age of 18 from May 1, 2021.
DOCS RUE VIP CULTURE IN GOVT HOSPITALS
Politicians and bureaucrats without severe illness demand preferential treatment, causing great hardship to the overstrained frontline, say doctors
SARS-COV-2 Re-Infection And Vaccine Development
The molecular mechanisms behind the human immune response to SARS-CoV-2 need to be examined thoroughly to design effective vaccines
Virus variants in the spotlight as number of reinfections and breakthroughs rise
Viloxazine for treatment of ADHD
Supernus Pharmaceuticals announced that the US FDA approved viloxazine extended-release capsules (Qelbree) for the treatment of attention-deficit hyperactivity disorder (ADHD) in paediatric patients 6 to 17 years of age.
“OUR CALL TO COUNTRIES IS TO DO BI-DIRECTIONAL TESTING FOR TB AND COVID-19”
DR LUCICA DITIU is the Executive Director of Stop TB Partnership— one of the most influential advocacy voices on global health and tuberculosis that provides support for a TB response to achieve a world without TB. A specialist in lung diseases from Romania, Dr Ditiu started her international career with the WHO in January 2000 as a medical officer for TB in Albania, Kosovo and FYR Macedonia within the disaster and preparedness unit. She has worked for the past 18 years with WHO and the UN system at every level: national, sub-regional, regional and global. At the helm of the Stop TB Partnership for the past eight years, Dr Ditiu has been relentless in pushing for the inclusion of everyone affected by TB. In an interaction with S HARACHAND, she speaks about the international body’s ambitious goal to make the world free of the curable infectious disease and how the programme has been impacted by various challenges, including the COVID-19 pandemic.
SHOULD A DOCTOR PAY FOR MRs?
Paid consultation from the pharma field force could run into several challenges
SECNIDAZOLE SHOWS HIGHER CURE RATES IN TRICHOMONIASIS
The use of antibiotic secnidazole was found to be effective in treating women with trichomoniasis, according to a recent phase 3 study now published in the journal Clinical Infectious Diseases.
ANTI-SARS-COV-2 MONOCLONAL ANTIBODIES TREATMENT GUIDELINES
The SARS-CoV-2 genome encodes four major structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N), as well as nonstructural and accessory proteins. The S protein is further divided into two subunits, S1 and S2, that mediate host cell attachment and invasion. Through its receptor-binding domain (RBD), S1 attaches to angiotensin-converting enzyme 2 (ACE2) on the host cell; this initiates a conformational change in S2 resulting in virus-host cell membrane fusion and viral entry.
CONVALESCENT PLASMA TREATMENT GUIDELINES
Plasma from donors who have recovered from COVID-19 may contain antibodies to SARS-CoV-2 that may help suppress the virus and modify the inflammatory response.1 The Food and Drug Administration (FDA) issued an Emergency Use Authorisation (EUA) for convalescent plasma for the treatment of certain hospitalised patients with COVID-19.
Future Medicine India Magazine Description:
Publisher: NextGen Science Media Pvt Ltd
Future Medicine is a monthly medical science and news magazine, specially designed and developed for the medical fraternity of India. It empowers clinicians with the knowledge of latest breakthroughs in science, provides prompt updates on emerging medical and industry trends. It imparts timely news, views and analysis of tomorrow’s science, along with a discussion forum of medical science experts, who can predict and influence the future of healthcare.
Future Medicine’s multi-format approach allows new-age medical and life sciences professionals to browse through topics that most appeal to them, put forth in an easy-to-understand and interesting manner. The primary focus is on bridging the gap between medical researchers and clinicians. Future Medicine ushers a refreshing change in the manner of scientific information access within the field of medical science.
- Cancel Anytime [ No Commitments ]
- Digital Only